Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
CHRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $2.43
Previous CloseN/A
Volume565.36K
Average Volume (3M)1.44M
Market Cap
$152.26M
Enterprise Value-$98.62M
Total Cash (Recent Filing)$237.64M
Total Debt (Recent Filing)$2.41M
Price to Earnings (P/E)5.5
Beta1.62
Next Earnings
Nov 10, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding116,227,270
10 Day Avg. Volume1,287,356
30 Day Avg. Volume1,438,557
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.65
Enterprise Value/Revenue-0.69
Enterprise Value/Gross Profit-1.22
Enterprise Value/Ebitda0.72
Forecast
1Y Price Target
$4.03Price Target Upside212.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial StabilityCoherus had $238M in cash at the end of the quarter, providing financial stability and operational runway into 2027.
Market PotentialWith the restructuring and divesture of Udenyca in the rear mirror, Coherus is better positioned to realize the $150M-$200M market potential of Loqtorzi in NPC alone.
Strategic TransitionCoherus has transitioned away from biosimilars and into a pure-play immuno-oncology company, with two novel assets approaching key data readouts that could unlock significant value.
Bears Say
Competitive EnvironmentCheckpoint inhibitors remain a crowded space dominated by some of the largest players in pharma, and Coherus' pipeline assets to pair with the PD1 are relatively early stage.
Earnings PerformanceNon-GAAP net loss of $0.34 per share in Q2 was $0.01 worse than forecast.
Revenue PerformanceQ1 net revenue of $40MM was below our $55MM forecast.
Coherus Biosciences News
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.66 and its highest was $2.43 in the past 12 months.
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is $152.26M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Nov 10, 2025 which is in 65 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Aug 07, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.17.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.32.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 116,227,270 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went down -6.818%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CHRS
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.03 (212.40% Upside)
$4.03 (212.40% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 73.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-860.65%
Trailing 12-Months
Asset Growth
-34.88%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
CHRS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong focus on revenue growth and strategic repositioning, with significant progress in financial management and pipeline development. However, challenges remain in the adoption of LOQTORZI in community settings and competitive pressures in pipeline development. The positive aspects of revenue growth and strategic alignment outweigh the challenges.View all CHRS earnings summariesCHRS Stock 12 Month Forecast
Average Price Target
$4.03
▲(212.40% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
XBiotech
―
Nautilus Biotechnolgy
―
Instil Bio
―
Genelux Corp.
―
Ownership Overview
1.13% Insiders
15.86% Mutual Funds
14.84% Other Institutional Investors
58.15% Public Companies and
Individual Investors